Your browser doesn't support javascript.
loading
Adverse effects associated with peribulbar injection of triamcinolone for the treatment of thyroid eye disease: a retrospective case series.
Barlatay, Joaquin Miguel Gonzalez; Boza, Carla Pagano; Basso, Tomaz Ortiz; Benavente, Mercedes; Hernández-Gauna, Guillermo Vicente; Premoli, Eduardo Jorge.
Affiliation
  • Barlatay JMG; Division of Orbital and Ophthalmic Plastic Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Boza CP; Division of Orbital and Ophthalmic Plastic Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Basso TO; Division of Orbital and Ophthalmic Plastic Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Benavente M; Division of Orbital and Ophthalmic Plastic Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Hernández-Gauna GV; Division of Orbital and Ophthalmic Plastic Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Premoli EJ; Division of Orbital and Ophthalmic Plastic Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Arq Bras Oftalmol ; 86(5): e20230063, 2023.
Article in En | MEDLINE | ID: mdl-35544933
ABSTRACT

PURPOSE:

Peribulbar injection of triamcinolone is an alternative treatment for thyroid eye disease; however the safety profile of this therapeutic option remains controversial. The aim of this study was to describe the occurrence of local and systemic adverse effects after peribulbar injection of triamcinolone in patients with thyroid eye disease.

METHODS:

This was a retrospective case series. Medical records of patients with thyroid eye disease treated with peribulbar injections of triamcinolone at a single academic institution between 2007 and 2019 were analyzed. Local and systemic complications were documented.

RESULTS:

A total of 123 patients were treated. Only 11 patients (8.9%) developed local complications. The most frequent complication was the presence of superficial eyelid ecchymosis (nine patients; 7.3%). Notably, systemic complications (hyperglycemic and suprarenal inhibition after stop treatment) occurred in two patients (1.6%). All complications were transient, and the patients did not have any long-term sequelae.

CONCLUSIONS:

Peribulbar injection of triamcinolone for the treatment of thyroid eye disease is linked to a very low rate of local or systemic complications. Prospective studies are warranted to delve into this topic.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Graves Ophthalmopathy Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Arq Bras Oftalmol Year: 2023 Document type: Article Affiliation country: Argentina Publication country: BR / BRASIL / BRASILE / BRAZIL / BRESIL

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Graves Ophthalmopathy Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Arq Bras Oftalmol Year: 2023 Document type: Article Affiliation country: Argentina Publication country: BR / BRASIL / BRASILE / BRAZIL / BRESIL